Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice
The goal of the present study was to determine the efficacy of osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of aggressive EGFR-mutant non-small cell lung cancer (NSCLC), compared to cisplatinum (CDDP) + pemetrexed (PEM)...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-04-01
|
| Series: | Translational Oncology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523319300336 |
| id |
doaj-2752c71a9e05436fb25ab8088b3e6cfc |
|---|---|
| record_format |
Article |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Takashi Higuchi Hiromichi Oshiro Zhiying Zhang Kentaro Miyake Norihiko Sugisawa Yuki Katsuya Norio Yamamoto Katsuhiro Hayashi Hiroaki Kimura Shinji Miwa Kentaro Igarashi Ming Zhao Michael Bouvet Shree Ram Singh Hiroyuki Tsuchiya Robert M Hoffman |
| spellingShingle |
Takashi Higuchi Hiromichi Oshiro Zhiying Zhang Kentaro Miyake Norihiko Sugisawa Yuki Katsuya Norio Yamamoto Katsuhiro Hayashi Hiroaki Kimura Shinji Miwa Kentaro Igarashi Ming Zhao Michael Bouvet Shree Ram Singh Hiroyuki Tsuchiya Robert M Hoffman Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice Translational Oncology |
| author_facet |
Takashi Higuchi Hiromichi Oshiro Zhiying Zhang Kentaro Miyake Norihiko Sugisawa Yuki Katsuya Norio Yamamoto Katsuhiro Hayashi Hiroaki Kimura Shinji Miwa Kentaro Igarashi Ming Zhao Michael Bouvet Shree Ram Singh Hiroyuki Tsuchiya Robert M Hoffman |
| author_sort |
Takashi Higuchi |
| title |
Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice |
| title_short |
Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice |
| title_full |
Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice |
| title_fullStr |
Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice |
| title_full_unstemmed |
Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice |
| title_sort |
osimertinib regresses an egfr-mutant cisplatinum- resistant lung adenocarcinoma growing in the brain in nude mice |
| publisher |
Elsevier |
| series |
Translational Oncology |
| issn |
1936-5233 |
| publishDate |
2019-04-01 |
| description |
The goal of the present study was to determine the efficacy of osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of aggressive EGFR-mutant non-small cell lung cancer (NSCLC), compared to cisplatinum (CDDP) + pemetrexed (PEM). The NSCLC cell line PC-9 expressing green fluorescence protein (PC-9-GFP) was implanted in the brain of nude mice and was treated with CDDP + PEM or AZD9291. Tumors were observed by non-invasive fluorescence imaging. AZD9291 treatment caused tumor regression in contrast to CDDP + PEM which had only a slight inhibitory effect. These results suggest that AZD9291 is a promising clinical option for NSCLC patients with brain metastasis. |
| url |
http://www.sciencedirect.com/science/article/pii/S1936523319300336 |
| work_keys_str_mv |
AT takashihiguchi osimertinibregressesanegfrmutantcisplatinumresistantlungadenocarcinomagrowinginthebraininnudemice AT hiromichioshiro osimertinibregressesanegfrmutantcisplatinumresistantlungadenocarcinomagrowinginthebraininnudemice AT zhiyingzhang osimertinibregressesanegfrmutantcisplatinumresistantlungadenocarcinomagrowinginthebraininnudemice AT kentaromiyake osimertinibregressesanegfrmutantcisplatinumresistantlungadenocarcinomagrowinginthebraininnudemice AT norihikosugisawa osimertinibregressesanegfrmutantcisplatinumresistantlungadenocarcinomagrowinginthebraininnudemice AT yukikatsuya osimertinibregressesanegfrmutantcisplatinumresistantlungadenocarcinomagrowinginthebraininnudemice AT norioyamamoto osimertinibregressesanegfrmutantcisplatinumresistantlungadenocarcinomagrowinginthebraininnudemice AT katsuhirohayashi osimertinibregressesanegfrmutantcisplatinumresistantlungadenocarcinomagrowinginthebraininnudemice AT hiroakikimura osimertinibregressesanegfrmutantcisplatinumresistantlungadenocarcinomagrowinginthebraininnudemice AT shinjimiwa osimertinibregressesanegfrmutantcisplatinumresistantlungadenocarcinomagrowinginthebraininnudemice AT kentaroigarashi osimertinibregressesanegfrmutantcisplatinumresistantlungadenocarcinomagrowinginthebraininnudemice AT mingzhao osimertinibregressesanegfrmutantcisplatinumresistantlungadenocarcinomagrowinginthebraininnudemice AT michaelbouvet osimertinibregressesanegfrmutantcisplatinumresistantlungadenocarcinomagrowinginthebraininnudemice AT shreeramsingh osimertinibregressesanegfrmutantcisplatinumresistantlungadenocarcinomagrowinginthebraininnudemice AT hiroyukitsuchiya osimertinibregressesanegfrmutantcisplatinumresistantlungadenocarcinomagrowinginthebraininnudemice AT robertmhoffman osimertinibregressesanegfrmutantcisplatinumresistantlungadenocarcinomagrowinginthebraininnudemice |
| _version_ |
1716757558231826432 |
| spelling |
doaj-2752c71a9e05436fb25ab8088b3e6cfc2020-11-24T21:09:44ZengElsevierTranslational Oncology1936-52332019-04-01124640645Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude MiceTakashi Higuchi0Hiromichi Oshiro1Zhiying Zhang2Kentaro Miyake3Norihiko Sugisawa4Yuki Katsuya5Norio Yamamoto6Katsuhiro Hayashi7Hiroaki Kimura8Shinji Miwa9Kentaro Igarashi10Ming Zhao11Michael Bouvet12Shree Ram Singh13Hiroyuki Tsuchiya14Robert M Hoffman15AntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Department of Orthopedic Surgery, Kanazawa University, Kanazawa, JapanAntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USAAntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USAAntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USAAntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USAAntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USADepartment of Orthopedic Surgery, Kanazawa University, Kanazawa, JapanDepartment of Orthopedic Surgery, Kanazawa University, Kanazawa, JapanDepartment of Orthopedic Surgery, Kanazawa University, Kanazawa, JapanDepartment of Orthopedic Surgery, Kanazawa University, Kanazawa, JapanDepartment of Orthopedic Surgery, Kanazawa University, Kanazawa, JapanAntiCancer, Inc., San Diego, CA, USADepartment of Surgery, University of California, San Diego, CA, USA; Address all correspondence to: Michael Bouvet, Department of Surgery, University of California, San Diego, CA, USA. or Shree Ram Singh, Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA. or Hiroyuki Tsuchiya, Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan. or Robert M Hoffman, AntiCancer, Inc., San Diego, CA, USA.Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA; Address all correspondence to: Michael Bouvet, Department of Surgery, University of California, San Diego, CA, USA. or Shree Ram Singh, Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA. or Hiroyuki Tsuchiya, Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan. or Robert M Hoffman, AntiCancer, Inc., San Diego, CA, USA.Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan; Address all correspondence to: Michael Bouvet, Department of Surgery, University of California, San Diego, CA, USA. or Shree Ram Singh, Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA. or Hiroyuki Tsuchiya, Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan. or Robert M Hoffman, AntiCancer, Inc., San Diego, CA, USA.AntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Address all correspondence to: Michael Bouvet, Department of Surgery, University of California, San Diego, CA, USA. or Shree Ram Singh, Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA. or Hiroyuki Tsuchiya, Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan. or Robert M Hoffman, AntiCancer, Inc., San Diego, CA, USA.The goal of the present study was to determine the efficacy of osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of aggressive EGFR-mutant non-small cell lung cancer (NSCLC), compared to cisplatinum (CDDP) + pemetrexed (PEM). The NSCLC cell line PC-9 expressing green fluorescence protein (PC-9-GFP) was implanted in the brain of nude mice and was treated with CDDP + PEM or AZD9291. Tumors were observed by non-invasive fluorescence imaging. AZD9291 treatment caused tumor regression in contrast to CDDP + PEM which had only a slight inhibitory effect. These results suggest that AZD9291 is a promising clinical option for NSCLC patients with brain metastasis.http://www.sciencedirect.com/science/article/pii/S1936523319300336 |